Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $112.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.33% to $112.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.7 million through Dec 2025, up 3.33% year-over-year, with the annual reading at $112.7 million for FY2025, 3.33% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $112.7 million in Q4 2025 for Viking Therapeutics, roughly flat from $112.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $112.7 million in Q4 2025 to a low of $74.8 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $92.6 million across 5 years, with a median of $90.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): fell 0.47% in 2022 and later skyrocketed 32.28% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $77.2 million in 2021, then fell by 0.47% to $76.8 million in 2022, then rose by 23.03% to $94.5 million in 2023, then increased by 15.35% to $109.0 million in 2024, then rose by 3.33% to $112.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for VKTX at $112.7 million in Q4 2025, $112.2 million in Q3 2025, and $112.1 million in Q2 2025.